Amgen Inc. (1AMGN)

Profile

https://www.amgen.com

Amgen Inc. is a leading biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. Its principal products target serious illnesses, including Enbrel for rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for plaque psoriasis, psoriatic arthritis, and Behçet's disease oral ulcers; Prolia for postmenopausal osteoporosis; XGEVA to prevent skeletal-related events; and Repatha to reduce risks of myocardial infarction, stroke, and coronary revascularization. Additional key offerings encompass Nplate for immune thrombocytopenia, KYPROLIS for relapsed or refractory multiple myeloma, Aranesp for anemia, EVENITY for osteoporosis, Vectibix for metastatic colorectal cancer, BLINCYTO for acute lymphoblastic leukemia, TEPEZZA for thyroid eye disease, and KRYSTEXXA for chronic refractory gout. Amgen also markets products like Neulasta, MVASI, AMJEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI. Founded in 1980 and headquartered in Thousand Oaks, California, with approximately 28,000 employees, Amgen plays a pivotal role in the biopharmaceutical sector by addressing unmet needs in oncology, inflammation, cardiovascular disease, bone health, and rare disorders, contributing significantly to global healthcare advancements.